Role of Intralipid drug in heart protection during heart bypass surgery

Phase 4

Completed

• Conditions: Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery

• Registration Number: CTRI/2018/12/016665
• Lead Sponsor: Sri Jayadeva Institute of Cardiovascular Sciences and Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2019-02-14
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

patients of either sex, aged between 18 years to 70 years posted for elective OFF PUMP CORONARY ARTERY BYPASS SURGERY (OPCAB) with left ventricular ejection fraction (LVEF) > 40 %

Exclusion Criteria

Combined valve and coronary surgery, onpump CABG, redo cardiac surgery, hyperlipidaemia, significant hepatic or renal dysfunction, uncontrolled hypertension, any disorder with immunological dysfunction (eg, malignancy or positive serological test for the HIV) in the last 6 months, preoperative treatment with nicorandil (an ATP-sensitive potassium channel opener), sulfonylurea (an ATP- sensitive potassium channel blocker)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Role of Intralipid in myocardial protection during OPCAB surgery which will be assessed with Troponin T and CK-MB serum levels measured postoperativelyTimepoint: Till 72th hour postoperatively

Secondary Outcome Measures

Name	Time	Method
Hemodynamic changes intraoperatively, inotropes requirement, postoperative Ejection Fraction, lipid levels, effect on Renal function tests and Liver function testsTimepoint: Till the patient is discharged